Altimmune Inc (NASDAQ: ALT) kicked off on Friday, down -22.77% from the previous trading day, before settling in for the closing price of $5.05. Over the past 52 weeks, ALT has traded in a range of $2.90-$8.75.
A company in the Healthcare sector has jumped its sales by 3.48% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 27.05%. With a float of $103.63 million, this company’s outstanding shares have now reached $104.34 million.
Altimmune Inc (ALT) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Altimmune Inc is 0.68%, while institutional ownership is 40.02%. The most recent insider transaction that took place on Mar 17 ’25, was worth 5,784. In this transaction Director of this company bought 1,000 shares at a rate of $5.78, taking the stock ownership to the 1,000 shares. Before that another transaction happened on Mar 13 ’25, when Company’s Chief Financial Officer bought 10,000 for $5.20, making the entire transaction worth $51,996. This insider now owns 10,000 shares in total.
Altimmune Inc (ALT) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.33 earnings per share (EPS), higher than consensus estimate (set at -0.34) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 27.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.04% during the next five years compared to 3.48% growth over the previous five years of trading.
Altimmune Inc (NASDAQ: ALT) Trading Performance Indicators
Take a look at Altimmune Inc’s (ALT) current performance indicators. Last quarter, stock had a quick ratio of 17.18. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 20347.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.07, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -1.24 in one year’s time.
Technical Analysis of Altimmune Inc (ALT)
Let’s dig in a bit further. During the last 5-days, its volume was 7.32 million. That was better than the volume of 3.58 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 10.07%.
During the past 100 days, Altimmune Inc’s (ALT) raw stochastic average was set at 20.97%, which indicates a significant increase from 3.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.42 in the past 14 days, which was higher than the 0.24 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.49, while its 200-day Moving Average is $4.65. However, in the short run, Altimmune Inc’s stock first resistance to watch stands at $4.38. Second resistance stands at $4.87. The third major resistance level sits at $5.14. If the price goes on to break the first support level at $3.62, it is likely to go to the next support level at $3.35. Assuming the price breaks the second support level, the third support level stands at $2.86.
Altimmune Inc (NASDAQ: ALT) Key Stats
The company with the Market Capitalisation of 406.94 million has total of 104,342K Shares Outstanding. Its annual sales at the moment are 20 K in contrast with the sum of -95,060 K annual income. Company’s last quarter sales were recorded 10 K and last quarter income was -19,010 K.
